Grace and Formac Announce Positive Data from Clinical Trial Demonstrating Use of Silica for Drug Delivery

W. R. Grace, in partnership with Formac Pharmaceuticals (Heverlee, Belgium), announced positive data from initial human studies of the companies' mesoporous silica-based drug delivery technology. This was the first-ever clinical study to demonstrate the bioavailability enhancing properties of silica in humans, Grace says. Improved bioavailability enables active pharmaceutical ingredients (API's) to more effectively absorb into the body. This technology opens up a viable new avenue for the development of poorly soluble compounds, Grace says. The bioavailability...

This information is only available to Chemical Week subscribers.

Forgot your user ID or password?
Click here to have it sent to you.

Email Address First Name Last Name

Not an IHS Chemical Week 24/7 member yet? Here's why you should be: Searchable online archive access of the last 2 years of Chemical Week. Print or digital magazine subscription Price and market change alerts Economic data and statistics Buyers' Guides Webcasts | whitepapers